DOT Oral Fluid Drug Testing: After Three Years, a Major Regulatory Barrier Is Finally Gone

Senior Business Development Manager
i3screen

The FDA’s October 6 decision clears a significant obstacle that has prevented DOT oral fluid drug testing from becoming a reality. Here’s why it matters and what happens next.

In May 2023, the Department of Transportation (DOT) published its final rule allowing oral fluid drug testing as an alternative to traditional urine testing for federally regulated drug testing programs. It was one of the most significant changes to DOT drug testing regulations in decades, giving employers another option for conducting drug tests and addressing some of the longstanding challenges associated with urine specimen collections.

There was just one problem. Despite the DOT’s approval, employers couldn’t actually use it.

More than three years later, that may finally be about to change. On October 6, 2026, the Food and Drug Administration (FDA) issued a final order removing a significant regulatory obstacle that had prevented laboratories from moving forward with oral fluid testing for federal programs.

The decision represents a major victory for the drug and alcohol testing industry, but understanding its significance requires understanding why oral fluid testing has been stuck for so long.

How Did We Get Here?

When DOT published its oral fluid final rule in 2023, it established the regulatory framework for using oral fluid specimens in federally regulated drug testing programs. The regulations addressed collection procedures, laboratory testing, collector qualifications, and the requirements employers would need to follow.

However, the ability to implement the new regulations depended on laboratories becoming certified by the Department of Health and Human Services (HHS) through its National Laboratory Certification Program (NLCP).

That’s where things became complicated and stalled.

Laboratories conducting federal drug testing must comply with strict testing standards, including requirements governing the testing systems and reagents used to analyze specimens. Certain clinical toxicology test systems intended for employment and insurance testing had already been exempted from the FDA’s 510(k) premarket notification requirements, but that exemption specifically excluded devices intended for federal drug testing programs.

For those unfamiliar with the FDA’s 510(k) process, it generally requires manufacturers to demonstrate that a medical device is substantially equivalent to another legally marketed device before it can be marketed.

In practical terms, a testing system that could qualify for an exemption when used for non-federal employment drug testing could still require additional FDA clearance when intended for a federal drug testing program.

This created a regulatory bottleneck. Laboratories were preparing to meet HHS certification requirements, but the FDA requirements affecting laboratory testing systems presented an additional obstacle and delays. Without resolving that issue, the industry couldn’t get the certified laboratories necessary to begin DOT oral fluid testing.

The result was frustrating for employers, laboratories, and service providers alike. DOT had established regulations permitting oral fluid testing, but the industry remained unable to put those regulations into practice.

What Did the FDA Change?

On October 6, 2026, the FDA published a final order expanding the existing 510(k) exemptions for certain clinical toxicology test systems to include devices intended for use in federal drug testing programs.

The order became effective immediately.

This means qualifying testing systems no longer require the additional 510(k) premarket notification simply because they are intended for federal drug testing programs. The exemptions remain subject to the limitations specified by the FDA, and manufacturers and laboratories must still comply with other applicable requirements.

It’s an important distinction. The FDA didn’t lower the standards for federally regulated drug testing or eliminate the laboratory certification process. It removed a regulatory requirement that had become an impediment to implementing an already approved testing methodology.

The decision also reflects the importance of industry advocacy. The National Drug and Alcohol Screening Association (NDASA), working alongside other industry stakeholders, helped bring attention to the issue and advocate for a resolution. The FDA’s final order follows its May 2026 proposal and public comment process, during which the agency received feedback from approximately 70 commenters.

It’s a good example of why industry involvement in the regulatory process matters. Regulations don’t always work together as intended, and sometimes the practical consequences don’t become apparent until the people responsible for implementing them encounter the obstacles.

Does This Mean DOT Oral Fluid Testing Can Begin?

Not quite, but we are significantly closer.

Before employers can use oral fluid testing under DOT regulations, at least two HHS-certified laboratories must be available to perform oral fluid testing. The requirement for two laboratories exists because DOT’s split-specimen procedures allow an employee to request testing of the split specimen at a second independent laboratory.

According to information shared with i3screen, five laboratories have submitted for certification through the NLCP. With the FDA obstacle removed, those laboratories now have a clearer path toward completing the certification process.

Once the required laboratory capacity is certified and available, DOT employers will be able to begin incorporating oral fluid testing into their programs in accordance with the regulations. Initially, this will mean using paper federal Custody and Control Forms (CCFs), since approval for electronic CCFs involves a separate process.

For now, employers should continue operating their existing DOT urine testing programs while monitoring the progress of laboratory certification.

An Important Milestone, but Not the Finish Line

The FDA’s decision is welcome news for an industry that has been waiting more than three years to put DOT oral fluid testing into practice. It removes a major obstacle and creates a clearer path toward offering employers an additional specimen collection methodology.

However, laboratory certification is only the first step toward widespread adoption.

Even after the necessary laboratories are certified, collection sites will need qualified collectors, appropriate collection devices, and procedures to support oral fluid testing. Employers will need to consider how the new methodology fits into their existing drug testing policies, and service providers will need to address ordering, pricing, collection networks, and electronic documentation.

At i3screen, we see this as an important development for our clients and the broader drug and alcohol testing industry. Our focus will be on helping employers, CRAs, TPAs, and other service providers understand when oral fluid testing becomes available and how to incorporate it into their programs effectively.

Removing the regulatory barrier is a significant accomplishment. Making oral fluid testing practical, accessible, and operationally efficient will be the next challenge.

In our next article, we’ll explore why widespread adoption of DOT oral fluid testing may take longer than expected, including the economics of collection devices, collector training, electronic custody and control forms, and the important decisions employers will need to make about how oral fluid testing fits into their programs.